6th Jun 2007 07:00
Hikma Pharmaceuticals Plc06 June 2007 Annual General Meeting of Hikma Pharmaceuticals PLC LONDON, 6 June 2007 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX:HIK), the multinational pharmaceuticals manufacturer, will hold its AnnualGeneral Meeting today in London. At the meeting, Samih Darwazah, Chairman andChief Executive of Hikma Pharmaceuticals PLC, will make the following statement: "I am pleased to report that, as anticipated, the Group is performing wellyear-to-date. We will announce our interim results for the six months ended 30June 2007 on 5 September 2007 and will publish an update on trading at the endof June, prior to entering our close period on 7 July 2007." - ENDS - Enquiries: Hikma Pharmaceuticals PLCSusan Ringdal +44 20 7399 2760Investor Relations Director Brunswick GroupJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the Middle East andNorth Africa ("MENA") region, the United States and Europe. In 2006, the Grouphad revenue of $317 million and profit attributable to shareholders of $55million. At 31 December 2006, the Group had over 2,443 employees. For news andother information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals